Last updated on June 2019

Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiphosPholipid Syndrome


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Thrombosis | Antiphospholipid Syndrome
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Be 18 years of age
  2. Have a clinical diagnosis of the APS for which the patient is receiving anticoagulation therapy for the secondary prevention of thrombosis

2.a. Anticoagulation is defined as warfarin sodium titrated at the discretion of the clinician to a target INR 2.5 (range 2-3), 3.0 (range 2.5-3.5), or 3.5 (range 3-4).

2. b. Should the patient be receiving some other form of anticoagulation (apixaban, rivaroxaban, edoxaban, dabigatran etexilate, low-molecular weight heparin) and are willing to be randomized to warfarin with a target INR 2.5 or apixaban 5 mg PO BID and they meet all other inclusion criteria

3. Have completed at least 6months of anticoagulation for the indication of thrombosis and are without acute neurologic symptoms consistent with thrombosis, CVA, or TIA for a minimum of six months.

4. Be willing to provide informed consent to contact the subjects anticoagulation provider for INRs and dosing as well as details regarding any adverse events

5. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug.

6. Women must not be breastfeeding

7. Women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug apixaban plus 5 half-lives of study drug apixaban (3 days) plus 30 days (duration of ovulatory cycle) for a total of 33 days post-treatment completion.

8. Males who are sexually active with women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug apixaban plus 5 half-lives of the study drug apixaban (3 days) plus 90 days (duration of sperm turnover) for a total of 93 days post-treatment completion.

9. Azoospermic males and women of childbearing potential who are continuously not heterosexually active are exempt from contraceptive requirements. However they must still undergo pregnancy testing.

10. Be willing to undergo magnetic resonance imaging (MRI) of the brain

Exclusion Criteria:

  1. Another indication for long-term anticoagulation for which no FDA approval of apixaban exists (e.g. mechanical heart valve)
  2. A life expectancy of less than 1 year
  3. Is unable to attend follow-up appointments
  4. Is participating in a conflicting clinical trial or has participated in a trial within the last 30 days
  5. Is receiving concomitant dual antiplatelet therapy
  6. Requires aspirin dose of greater than 165mg daily
  7. A hemoglobin level of less than 8 mg per deciliter
  8. A platelet count of less than 50,000 per cubic millimeter
  9. Serum creatinine level of more than 2.5 mg per deciliter (221 mol per liter) or a calculated creatinine clearance of less than 25 ml per minute
  10. Alanine aminotransferase or aspartate aminotransferase level greater than 2 times the upper limit of the normal range
  11. A total bilirubin more than 1.5 times the upper limit of the normal range.
  12. Have active cancer for which treatment (chemotherapy/radiation therapy) is being delivered or has been delivered within the last 3 months
  13. Are actively receiving a strong dual inhibitor of CYP3A4 and P-gp, such as:

13.a Ketoconazole 13.b Itraconazole 13.c Ritonavir 13.d clarithromycin

14. Are actively taking a strong dual inducer of CYP3A4 and P-gp, such as: 14.a rifampin 14.b carbamazepine 14.c phenytoin 14.d St. John's wort

15. Intend pregnancy or breastfeeding within the next year

16. Have a known allergy to apixaban, rivaroxaban, or edoxaban

17. Have experienced thrombosis while receiving warfarin at a target INR of 2-3 and have been assigned a higher target INR at the discretion of their clinician.

18. Patients with active pathological bleeding.

19. A history of arterial thromboembolism (e.g., stroke, myocardial infarction or other arterial thrombosis)

20. Requires clopidogrel, tigacrolor, prasugrel, or another P2Y12 inhibitor

21. Have a history of catastrophic APS (CAPS) as defined by clinical routine

22. Have radiographic evidence of prior arterial thrombosis on MRI as defined per clinical routine upon screening MRI

23. At the discretion of the investigator are considered to not be candidates secondary to s a safety concern.

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.